METHODS FOR TREATMENT USING SELECTIVE BCL-2 INHIBITORS Russian patent published in 2016 - IPC A61K31/496 A61P37/00 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: group of inventions concerns using 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulphonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide, or 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulphonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide, or their pharmaceutically acceptable salts for preparing drug. This device can be used for treating autoimmune diseases-systemic lupus erythematosus, lupous nephritis or Sjogren's syndrome in patient administered with therapeutically effective amount of this agent, for example, in range from 0.001 mg/kg to 1,000 mg/kg. Drug can be used in combination with binding protein for additional increase of efficiency of compound in desired place action.

EFFECT: inventions provide most selective inhibition of activity antiapoptotic Bcl-2 proteins with most low affinity than inhibition of activity of other proteins of family Bcl-2, including Bcl-x_L, that require smaller doses of used compounds.

12 cl, 9 ex, 12 dwg, 4 tbl